75.21

5.37% 3.83

After Hours: 75.16 -0.05 -0.07%

Cytokinetics Inc (CYTK)

Overview News Price History Option Chain Financials Why CYTK Down? Discussions Forecast Stock Split

Cytokinetics Inc stock is traded at $75.21, with a volume of 3.97M. It is up +5.37% in the last 24 hours and down -0.84% over the past month. Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Previous Close:

$71.38

Open:

$73

24h Volume:

3.97M

Relative Volume:

1.69

Market Cap:

$10.21B

Revenue:

$105.82M

Net Income/Loss:

$-829.61M

P/E Ratio:

-10.99

EPS:

-6.8429

Net Cash Flow:

$-548.92M

1W Performance:

+9.88%

1M Performance:

-0.84%

6M Performance:

+21.27%

1Y Performance:

+122.65%

1-Day Range:

$72.15

$77.00

1-Week Range:

$66.63

$77.00

52-Week Range:

$31.99

$80.20

Cytokinetics Inc Stock (CYTK) Company Profile

Name

Cytokinetics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

(650) 624-3000

Address

350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

673

Twitter

@Cytokinetics

Next Earnings Date

2026-08-06

Latest SEC Filings

CYTK's Discussions on Twitter

Compare CYTK vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYTK Cytokinetics Inc	75.21	9.69B	105.82M	-829.61M	-548.92M	-6.8429
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Wells Fargo	Overweight
Jan-28-26	Resumed	Barclays	Overweight
Dec-18-25	Upgrade	Goldman	Neutral → Buy
Jul-30-25	Resumed	Raymond James	Mkt Perform
Apr-24-25	Initiated	Barclays	Overweight
Feb-07-25	Initiated	Citigroup	Buy
Jan-22-25	Initiated	Stifel	Buy
Nov-08-24	Initiated	RBC Capital Mkts	Outperform
Aug-13-24	Downgrade	Goldman	Buy → Neutral
Jan-24-24	Downgrade	UBS	Buy → Neutral
Jan-05-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-07-23	Initiated	B. Riley Securities	Buy
Aug-15-23	Initiated	SVB Securities	Outperform
Feb-17-23	Initiated	BofA Securities	Neutral
Dec-23-22	Reiterated	Needham	Buy
Dec-20-22	Initiated	Truist	Buy
Oct-11-22	Initiated	UBS	Buy
Jan-28-22	Initiated	Goldman	Buy
Dec-22-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	JP Morgan	Overweight
Oct-07-21	Initiated	Jefferies	Buy
Mar-12-21	Initiated	Wolfe Research	Outperform
Feb-18-21	Initiated	Barclays	Overweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-29-20	Initiated	Goldman	Neutral
Jul-10-20	Initiated	Raymond James	Strong Buy
May-05-20	Initiated	Mizuho	Buy
Apr-09-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-10-18	Resumed	Morgan Stanley	Equal-Weight
Nov-22-17	Reiterated	Morgan Stanley	Overweight
Nov-22-17	Downgrade	Needham	Strong Buy → Buy
Nov-21-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Initiated	Morgan Stanley	Overweight
Mar-08-17	Initiated	Rodman & Renshaw	Buy
Feb-06-17	Upgrade	Needham	Buy → Strong Buy
Dec-16-16	Initiated	Cantor Fitzgerald	Overweight
Jul-28-16	Reiterated	Needham	Buy
Nov-10-15	Reiterated	FBR Capital	Outperform
Nov-09-15	Reiterated	ROTH Capital	Buy
Jul-24-15	Reiterated	MLV & Co	Buy
Dec-31-14	Reiterated	ROTH Capital	Buy
Nov-04-14	Upgrade	MLV & Co	Hold → Buy
Apr-28-14	Reiterated	Needham	Buy

View All

Cytokinetics Inc Stock (CYTK) Latest News

Jun 15, 2026

Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade - Stock Titan

Jun 15, 2026